Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arepanrix H1N1 Vaccine in Young Children
NCT01000831Phase 4Completed
- Sponsor
- University of British Columbia
- Start
- Nov 2009
- Primary completion
- Feb 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in Influenza A H1N1 (H1N1), sponsored by University of British Columbia. Primary endpoints: Safety and immunogenicity of one and two doses Arepanrix at Day 42 and Rapid Trial at Day 42. Started Nov 2009; status: completed.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
Influenza A H1N1 (H1N1)
Beyond the preview
Go deeper on NCT01000831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000831.